US009408909B2

(12) **United States Patent**
Thielemans et al.

(10) **Patent No.: US 9,408,909 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **ENHANCING THE T-CELL STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS IN VITRO AND IN VIVO AND ITS USE IN VACCINATION**

(71) Applicant: **Vrije Universiteit Brussel**, Brussels (BE)

(72) Inventors: **Kris Maria Magdalena Thielemans**, Wilrijk (BE); **Aude Bonehill**, Essene (BE)

(73) Assignee: **Vrije Universiteit Brussel**, Brussels (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/974,563**

(22) Filed: **Aug. 23, 2013**

(65) **Prior Publication Data**

US 2014/0056939 A1 Feb. 27, 2014

Related U.S. Application Data

(63) Continuation-in-part of application No. 13/593,393, filed on Aug. 23, 2012, which is a continuation-in-part of application No. 12/677,476, filed as application No. PCT/EP2008/062174 on Sep. 12, 2008, now Pat. No. 8,476,419.

(30) **Foreign Application Priority Data**

Sep. 14, 2007 (WO) PCT/EP2007/059732

(51) **Int. Cl.**

A61K 48/00	(2006.01)
A61K 39/39	(2006.01)
A61K 39/00	(2006.01)
C12N 5/0784	(2010.01)

(52) **U.S. Cl.**

CPC ***A61K 39/39*** (2013.01); ***A61K 39/0011*** (2013.01); ***C12N 5/0639*** (2013.01); *A61K 2039/5154* (2013.01); *A61K 2039/5156* (2013.01); *A61K 2039/5158* (2013.01); *A61K 2039/53* (2013.01); *A61K 2039/54* (2013.01); *C12N 2510/00* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,969,609	B1	11/2005	Schlom et al.	
7,378,277	B2	5/2008	Hwu et al.	
7,754,482	B2	7/2010	Riley et al.	
2003/0202963	A1 *	10/2003	Crystal et al.	424/93.2
2005/0059624	A1 *	3/2005	Hoerr et al.	514/44
2006/0188490	A1 *	8/2006	Hoerr et al.	424/93.21
2011/0027310	A1 *	2/2011	Medin et al.	424/204.1

FOREIGN PATENT DOCUMENTS

WO	WO 2005/012509	2/2005
WO	WO 2006/042177	4/2006
WO	WO 2007/078196	7/2007

OTHER PUBLICATIONS

Thornburg et al., 2000, J. Immunother. vol. 23: 412-418.*

Mor et al., 2005, J. Immunol. vol. 175: 3439-45.*

Curran et al., 2010, PNAS, vol. 107: 4275-80.*

Gavrilov et al., 2012, Jayle J. Biol. Med. vol. 85: 187-200.*

Kreiter et al., 2010, Canc. Res. vol. 70:9031-40.*

Weide et al., 2009, J. Immunother. vol. 32: 498-507.*

Huang et al.,2005, Canc. Res. vol. 65: 5009-14.*

International Search Report for International Application No. PCT/EP2008/062174, mailed on Dec. 30, 2008.

Abdel-Wahab, et al., "Cotransfection of DC with TLR4 and MART-1 RNA Induces MART-1 Specific Responses," Journal of Surgical Research, vol. 124, No. 2, pp. 264-273, Apr. 2005.

Bonehill, et al. "Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation with CD40L, CD70 and Constitutively active TLR4 Encoding mRNA," Molecular Therapy, vol. 16, No. 6, pp. 1170-1180, Jun. 2008.

Croft, "Control of Immunity by the TNFR-related Molecule OX40 (CD134)," The Annual Review of Immunology, vol. 28, pp. 57-78, 2010.

Hori, "Developmental Plasticity of Foxp3+ regulatory T Cells," Current Opinion in Immunology, vol. 22, pp. 575-582, 2010.

Hori, "Regulatory T Cell Plasticity: Beyond the Controversies," Trends in Immunology vol. 32, No. 7, pp. 295-300, Jul. 2011.

Jonuleit, et al. "Pro-inflammatory Cytokines and Prostaglandins Induce Maturation of Potent Immunostimulatory Dendritic Cells under Fetal Calf Serum-free Conditions," European Journal of Immunology, vol. 27, No. 12, pp. 3135-3142, Dec. 1997.

Koch, et al. "T-bet Controls Regulatory T Cell Homeostasis and Function During Type-1 Inflammation," Nature Immunology, vol. 10, No. 6, pp. 595-602, Jun. 2009.

Kubo, et al. "Regulatory T Cell Suppression and Anergy are Differentially Regulated by Proinflammatory Cytokines Produced by TLR-activated Dendritic Cells," The Journal of Immunology, vol. 173, pp. 7249-7258, 2004.

(Continued)

Primary Examiner — Amy Juedes

(74) *Attorney, Agent, or Firm* — Dinsmore & Shohl LLP

(57) **ABSTRACT**

We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).

11 Claims, 93 Drawing Sheets